News | Structural Heart | January 20, 2016

Antarctic Explorer Shackleton Posthumously Diagnosed with ‘Hole in the Heart’

Inquiry on the 100th anniversary of the Endurance expedition reveals atrial septal defect

Ernest Shackleton, hole in the heart, Endurance 100th anniversary, Ian Calder

January 20, 2016 — On the 100th anniversary of the Endurance expedition to Antarctica led by Sir Ernest Shackleton, doctors writing in the Journal of the Royal Society of Medicine believe the explorer may have had the congenital defect commonly known as a 'hole in the heart'. Shackleton was capable of severe exertion and made the first crossing of the mountains and glaciers of South Georgia without any health problems. During other expeditions, however, he alarmed his companions with repeated attacks of breathlessness and weakness.

Historians have pondered the cause of Shackleton's physical breakdowns. Inspired by his own experience of crossing South Georgia in a party led by mountaineer Stephen Venables, retired anaesthetist Ian Calder, M.D., with consultant cardiologist Jan Till, M.D., made use of material held in the Scott Polar Research Institute in Cambridge to diagnose an atrial septal defect (hole in the heart).

"The evidence rests in diary entries made by Dr. Eric Marshall, the medical officer of Shackleton's second expedition to the Antarctic in 1907-9," said Calder. "The detection and treatment of an atrial septal defect is now reasonably straightforward, but was not available to Shackleton."

The authors believe that Shackleton knew he had something wrong with his heart because he avoided being examined by doctors who might have tried to prevent him going to Antarctica.

Calder commented, "Some may feel that Sir Ernest was irresponsible in undertaking the leadership of Antarctic expeditions if he suspected a problem, but to paraphrase Dr. Johnson, there is seldom a shortage of prudent people, whilst the great things are done by those who are prepared to take a risk."

Shackleton died of a heart attack in 1922, a few hours after arriving in South Georgia at the beginning of his fourth expedition. He was 47 years of age.

For more information: www.sagepublications.com

Related Content

Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Siemens Healthineers Receives FDA Clearance for TrueFusion Structural Heart Disease Feature
Technology | Cardiovascular Ultrasound| September 06, 2017
The U.S. Food and Drug Administration (FDA) has cleared TrueFusion, a new cardiovascular application from Siemens...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
Abbott Initiates U.S. Pivotal Study of Amplatzer Device for Patent Ductus Arteriosus
News | Congenital Heart| September 05, 2017
Abbott announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Sponsored Content | Videos | Heart Valve Technology| August 30, 2017
Azeem Latib, M.D., MBBCh, FCP, interventional cardiologist at Columbus Hospital in Milan, Italy, discusses the latest
Overlay Init